Cogprints
Login | Create Account

Clinical significance of hypertension, diabetes and inflammation, as predictor of cardiovascular disease

Arumugam Vijaya Anand , Mubarack Muneeb , Natarajan Divya , Ramalingam Senthil , Mohamed Mydeen Abdul Kapoor, Jayaraman Gowri, Tajuddin Nargis Begum (2011) Clinical significance of hypertension, diabetes and inflammation, as predictor of cardiovascular disease. [Journal (Paginated)]

Full text available as:

[img]
Preview
PDF (Clinical significance of hypertension, diabetes and inflammation, as predictor of cardiovascular disease) - Published Version
Available under License Creative Commons Attribution No Derivatives.
153Kb

Abstract

Despite the availability of effective primary and secondary therapies, cardiovascular disease (CVD) remains the leading cause of morbidity and mortality. Use of traditional cardiovascular risk factors is imprecise and predicts less than one half of future cardiovascular events. Diabetes generally results in early death from CVD. Hypertension also increases the risk of CVD. Patients with hypertension and diabetes with accompanied dyslipidemia are soft targets of cardiovascular deaths. The growing appreciation of the role of inflammation in atherogenesis has focused attention on whether circulating levels of inflammatory biomarkers may help identify those at risk of future cardiovascular events. High-sensitivity C-reactive protein (hsCRP) has been investigated extensively as a marker of inflammatory response that is useful in predicting the risk of CVD. The role of hsCRP and the combined effect of diabetes and hypertension in the prediction of risk of CVD is less defined. The present study was therefore designed to evaluate the association of hsCRP, diabetes and hypertension in the prediction of risk of CVD. Hundred patients were recruited for the study, of which, fifty belongs to control and fifty were test group. For the entire study population hsCRP, sugar level, hypertension and lipid profiles were measured. Considerable variability was observed between control and test group. Among the patients with complications (diabetes and hypertension), there was a significant elevation of hsCRP and lipid profile than the control. It was found that the measurement of hsCRP in CVD patients with diabetes and hypertension may prove to be even a better marker of risk response.

Item Type:Journal (Paginated)
Keywords:Dyslipidemia, metabolic syndrome, inflammation
Subjects:JOURNALS
ID Code:7189
Deposited By:International Journal of Biological and Medical Research , (IJBMR) ISSN:0976-6685
Deposited On:16 Feb 2011 19:46
Last Modified:11 Mar 2011 08:57

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

References

[1] Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, Evans A, Ferrario M, Tuomilehto J. Estimation of contribution of changes in classic risk factors to trends in coronary event rates across the WHO MONICA Project populations. Lancet. 2000; 355:675-687.

[2] Preventive cardiology. How can we do better? Proceedings of the 33rd Bethesda Conference. Bethesda, Maryland, USA. J Am Coll Cardiol. 2002; 40:580-651.

[3] Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8- year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107:391-397.

[4] Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342:836-843.

[5] Ridker PM., Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336:973-979.

[6] Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998; 98:839-844.

[7] Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005; 294:326-333.

[8] Cannon CP, Braunwald E, McCabe CH. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350:1495-504.

[9] JNC VI. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157:2413-2446.

[10] Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157: 2413-2446.

[11] Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older persons with isolated systolic hypertension. Lancet. 1997; 1:757-764.

[12] Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation. 1999; 100:354-360.

[13] van den Hoogen PCW, Feskens EJM, Nagelkerke NJD, Menotti A, Nissinen A, Kromhout D, for the Seven Countries Research Group. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med. 2000; 342:1-8.

[14] Rodgers A, MacMahon S. Blood pressure and the global burden of cardiovascular disease. Clin Exp Hypertens. 1999; 21:543-552.

[15] Vasan RS, Larson MG, Evans JC, O'Donnell CJ, Levy D. High normal blood pressure and risk of cardiovascular disease: the Framingham Heart Study. Circulation. 1999; 100(18 suppl 1):34.

[16] Cutler JA, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control: what has been learned from clinical trials. In: Laragh JH, Brenner BM eds. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press, 1995; 253-270.

[17] Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older persons with isolated systolic hypertension. Lancet. 1997; 1:757-764.

[18] Gavin JR III, Alberti KGMM, Davidson MB, DeFronzo RA, Drash A, Gabbe SG, Genuth S, Harris MI, Kahn R, Keen H, Knowler WC, Lebovitz H, Maclaren NK, Palmer JP, Raksin P, Rizza RA, Stern MP. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1998; 21(suppl):S5-S19.

[19] Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, and Bennett PH eds. Diabetes in America, 2nd edition. Bethesda, MD: U.S. Department of Health and Human Services, 1995; 429-448.

[20] Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb. 1992; 12:647-656.

[21] Herlitz J, Karlson BW, Edrardsson N, Emanuelsson H, Hjalmarson A. Prognosis in diabetics with chest pain or other symptoms suggestive of acute myocardial infarction. Cardiology. 1992; 80:237-425.

[22] Miettinen H, Lehto S, Salomaa V, Mähönen M, Niemelä M, Haffner SM, Pyörälä K, Tuomilehto J, for the FINMONICA Myocardial Infarction Register Study group. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care. 1998; 21:69-75.

[23] Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 993; 329:977-986.

[24] Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Meseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994; 331:417-424.

[25] Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998; 31:1460-1465.

[26] Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol. 2000; 35:1535-1542.

[27] Lenderink T, Boersma E, Heeschen C. Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA. Eur Heart J. 2003; 24:77-85.

[28] Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000; 343:1139-1147.

[29] Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002; 105:1760-1763.

[30] Yusuf S, Hawken S, Ounpuu S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364:937-952.

[31] Hung J, Knuiman MW, Divitini ML, Davis T, Beilby JP. Prevalence and risk factor correlates of elevated C-reactive protein in an adult Australian population. Am J Cardiol. 2008; 101(2):193-198.

[32] Michowitz Y, Arbel Y, Wexler D, Sheps D, Rogowski O, Shapira I, Berliner S, Keren G, George J, Roth A. Predictive value of high sensitivity CRP in patients with diastolic heart failure. Int J Cardiol. 2008; 125:347-351.

Metadata

Repository Staff Only: item control page

Cogprints is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.